AIM ImmunoTech
11 hedge funds and large institutions have $970K invested in AIM ImmunoTech in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
168% more capital invested
Capital invested by funds: $362K → $970K (+$608K)
57% more funds holding
Funds holding: 7 → 11 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.25M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$957K |
| 3 |
Morgan Stanley
New York
|
+$349K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$301K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$24.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.18K |
AIM Hedge Fund Activity: Q3 2019 in Review
11 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2019, worth a combined $970K — up 168% from $362K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AIM positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.25M. The largest seller was UBS Group, exiting entirely with an estimated $2.18K sold.
- 11 institutional investors held AIM ImmunoTech (AIM) as of Q3 2019, up from 7 in Q2 2019.
- Funds reported $970K of AIM ImmunoTech stock for Q3 2019, up 168% quarter-over-quarter.
- 5 funds opened new AIM ImmunoTech positions in Q3 2019 and 1 closed out, a net change of +4 holders.
- The largest AIM ImmunoTech buyer in Q3 2019 was Anson Funds Management, an estimated $1.25M added.
- The largest AIM ImmunoTech seller in Q3 2019 was UBS Group, an estimated $2.18K sold.
Based on aggregated 13F filings for Q3 2019.